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Abstract
Introduction: Methotrexate (MTX) is a cornerstone of treatment in a wide variety of inflammatory conditions,
including juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM). However, owing to its narrow
therapeutic index and the considerable interpatient variability in clinical response, monitoring of adherence to MTX
is important. The present study demonstrates the feasibility of using methotrexate polyglutamates (MTXPGs) as a
biomarker to measure adherence to MTX treatment in children with JIA and JDM.
Methods: Data were collected prospectively from a cohort of 48 children (median age 11.5 years) who received
oral or subcutaneous (SC) MTX therapy for JIA or JDM. Dried blood spot samples were obtained from children by
finger pick at the clinic or via self- or parent-led sampling at home, and they were analysed to determine the
variability in MTXPG concentrations and assess adherence to MTX therapy.
Results: Wide fluctuations in MTXPG total concentrations (>2.0-fold variations) were found in 17 patients receiving
stable weekly doses of MTX, which is indicative of nonadherence or partial adherence to MTX therapy. Age
(P = 0.026) and route of administration (P = 0.005) were the most important predictors of nonadherence to MTX
treatment. In addition, the study showed that MTX dose and route of administration were significantly associated
with variations in the distribution of MTXPG subtypes. Higher doses and SC administration of MTX produced higher
levels of total MTXPGs and selective accumulation of longer-chain MTXPGs (P < 0.001 and P < 0.0001, respectively).
Conclusions: Nonadherence to MTX therapy is a significant problem in children with JIA and JDM. The present
study suggests that patients with inadequate adherence and/or intolerance to oral MTX may benefit from SC
administration of the drug. The clinical utility of MTXPG levels to monitor and optimise adherence to MTX in
children has been demonstrated.
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Introduction
Methotrexate (MTX) is an effective disease-modifying
antirheumatic drug (DMARD) widely used in children
to treat a variety of autoimmune and inflammatory con-
ditions, including juvenile idiopathic arthritis (JIA) and
juvenile dermatomyositis (JDM) [1–6]. Owing to its effi-
cacy and cost-effectiveness, MTX is likely to remain a
cornerstone of treatment [5, 7]. However, because of the
considerable interpatient variability in clinical response,
absorption difficulties and a wide spectrum of side effects,
monitoring of adherence to MTX is important [4, 8–11].
MTX is a prodrug activated intracellularly to form
methotrexate polyglutamates (MTXPGs) through se-
quential addition of glutamic acid residues by the en-
zyme folylpolyglutamate synthase (FPGS) [12, 13].
Within the cell, MTXPGs bind to and inhibit dihydrofo-
late reductase and other folate pathway enzymes re-
quired for purine and pyrimidine synthesis, thereby
providing anti-inflammatory effects [14, 15]. Polygluta-
mation of MTX promotes its retention intracellularly,
resulting in enhanced inhibitory effects against its target
enzymes. Compared with MTX itself, long-chain MTXPGs
have been shown to confer much more potent inhibition
of target enzymes within folate metabolism [13, 16, 17].
The clinical value of monitoring serum concentrations of
the parent drug is therefore very limited and generally not
practical, because approximately 95 % of MTX dose is
metabolised within 24 h of administration [13, 18, 19].
However, monitoring MTXPGs as a surrogate bio-
marker for drug exposure offers a potential tool to
assess adherence to long-term therapy in patients
with chronic inflammatory conditions (due to their
long half-life of elimination) [20, 21]. Evidence sug-
gests that MTXPGs may be associated with the effi-
cacy and toxicity of MTX treatment in rheumatoid
arthritis, and some investigators have advocated rou-
tine monitoring of MTXPGs for that reason [22–25].
Apart from one recent study in children with JIA
[26], adherence rates to MTX treatment in paediatric
patients with rheumatologic diseases, including JIA
and JDM, have not been previously reported. Studies
investigating MTX adherence in adult rheumatology
patients have been based mainly on prescription data
[27–29], electronic pill counts [30] or self-reported
measures [31]. Reported nonadherence to medications
in adult patients with JIA ranges from 8 to 48 %,
with rates fluctuating depending on the time of evalu-
ation and method used for adherence assessment
[32–37]. Risk factors for lack of adherence could in-
clude demographic variables such as the patient’s be-
ing an adolescent or having low socioeconomic status
[32, 34, 38], having concerns about side effects of ad-
ministered drug or lack of belief about the necessity
of treatment [31, 39].
In the present study, adherence to MTX treatment in
a cohort of children with JIA and JDM was evaluated. A
method for measuring MTXPG concentrations using the
novel dried blood spot (DBS) sampling technique was
developed by our group [40] and applied in the present
study to evaluate adherence to prescribed MTX therapy
in children. A secondary aim of the study was to charac-
terise the pattern of variability in MTXPG concentrations
and determine the clinical variables and biochemical pa-
rameters that could predict the observed variability in
MTX metabolite levels.
Methods
Study population
A total of 49 paediatric patients with JIA or JDM
were recruited into this study from three paediatric
outpatient rheumatology clinics in three different cen-
tres: (1) Musgrave Park Hospital, Belfast, Northern
Ireland; (2) Alder Hey Children’s NHS Foundation
Trust, Liverpool, UK; and (3) Great Ormond Street
Hospital for Children NHS Foundation Trust, London.
Patients between the ages of 4 and 17 years who were re-
ceiving stable MTX weekly doses [oral or subcutaneous
(SC)] for at least 2 months were identified for inclusion in
the study.
Participants were asked to provide one DBS sample
for analysis of MTX metabolite content during a regu-
larly scheduled clinic visit. Samples were collected by
finger prick from each child by spotting drops of blood
(two spots per child) directly onto a Guthrie card. For
children 5 years of age or older, parents and/or older
children were also asked to take two additional DBS
samples at home 4 weeks apart, dry them overnight at
room temperature and mail them to our laboratory in
prepaid mailer kits for analysis.
Accurate information about MTX dosing and times of
sampling were recorded prospectively during the clinic
visit using bespoke collection forms. The following data
were also collected from patient case notes and clinical
chemistry records and recorded in these collection
forms: age, weight, height, medical history (date of diag-
nosis, other medical conditions and current medica-
tions), biochemical parameters, clinical outcome and
records of side effects experienced (e.g., nausea and
vomiting). For samples obtained at home, the mailer kits
included appropriate collection forms mailed to the pa-
tient and/or the patient’s parent in advance of the sam-
pling time, with clear instructions on how to take the
sample and fill in the form.
Ethical considerations
The study was approved by the Office for Research
Ethics Committees in Northern Ireland (reference num-
ber 10/NIR03/33). Patients were included in the study
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only after their parents or legal guardians had been fully
informed and had signed the study consent form. In
addition, verbal or written assent was obtained from older
children (≥6 years) before enrolment into the study.
Measurement of methotrexate polyglutamate
concentrations
DBS concentrations of MTX active metabolites (MTXPGs
up to the fifth order of glutamation, MTXPG5) were mea-
sured by using a selective and sensitive reverse-phase
liquid chromatography–tandem mass spectrometry
(LC-MS/MS) methodology that we previously devel-
oped and validated [40]. Intraday and interday coeffi-
cients of variation were less than 15 %, and the limits
of detection for individual MTXPGs (MTXPG1–5) and
total concentration of methotrexate polyglutamate
(MTXPGtotal) were determined at 1.6 nmol/L and
1.5 nmol/L, respectively.
Differences in MTXPG concentrations between pa-
tients were evaluated as a function of age, sex, diagnosis
and route of administration (SC or oral). To differentiate
the effect of these factors from dose- or weight-related
changes, MTXPG concentrations were normalised by
administered dose of MTX (per kilogram of patient
weight or per square metre of body surface area) and
expressed as nanomoles per litre per milligram or nano-
moles per litre per milligram per square metre.
Assessment of adherence
The pattern of variability in MTXPG levels as a function
of time was evaluated over two consecutive 4-week inter-
vals during which patients were receiving stable MTX
doses. Nonadherence was assumed if a patient had wide
variations (≥2.0-fold) in MTXPG levels on different occa-
sions while prescribed the same dose of MTX. A ratio of
2.0-fold was chosen as the cutoff point because similar
values have been suggested for identifying patients nonad-
herent to long-term therapy in chronic diseases [41, 42].
Statistical analysis
Statistical analysis was performed using IBM SPSS ver-
sion 21 software (IBM SPSS, Armonk, NY, USA). The
results were expressed as the median and range values
or as frequencies. Descriptive statistics were used to
characterise the variability in individual MTXPG1–5 and
MTXPGtotal concentrations between different groups of
patients. Univariate associations between MTXPG con-
centrations and demographic or clinical characteristics
were analysed using the Mann–Whitney U test or the
Kruskal–Wallis test, as appropriate. Group differences in
the proportion of patients with ≥2.0-fold variation in
their MTXPG levels were explored using χ2 tests with 1
degree of freedom or Fisher’s exact test, as appropri-
ate. Comparison of the median fold ratio of highest
to lowest MTXPG concentration was performed using
the Mann–Whitney U test. All analyses were two-
sided, with P values <0.05 considered significant.
Results
Demographic characteristics of the study population
Of the 49 patients recruited into the study, 32 (65 %)
had an underlying diagnosis of JIA and 17 had JDM.
The median age (range) of the population was 11.5 years
(4–17 years), and 67 % were female. All patients were
being treated with weekly MTX (median 0.31 mg/kg,
equivalent to 10.2 mg/m2) for long durations (median
2.8 years, 5 months–10 years), and 41 % were receiving
SC MTX. One patient did not provide a DBS sample at
the clinic and therefore was not included in the analysis.
Of the patients included in the analysis (n = 48), 40
(83 %) provided at least two DBS samples during the
study period and 60 % received oral folic acid supple-
mentation (median dose 5 mg/week). The demographic
and clinical characteristics of the study participants are
shown in Table 1.
Distribution of methotrexate polyglutamate
concentrations and effect of administered dose
In our cohort of 48 patients with clinic DBS samples,
the median MTXPGtotal was 91.5 nmol/L (range 3.5–
470.4 nmol/L). Analysis of the correlation between
MTXPGtotal and individual MTXPG subtypes revealed a
very high correlation (R = 0.91, P < 0.0001) between total
MTXPGs and MTX triglutamate (MTXPG3). Consider-
able internal correlations of the concentrations within
Table 1 Demographic and clinical characteristics of study
patients
Characteristics Valuesa (n = 49)
Age (yr) 11.5 (4–17)
Sex [females, n (%)] 33 (67.3 %)
Weight (kg) 41 (13.4–119.7)
Height (cm) 146 (95–178)
MTX weekly dose (mg) 13.75 (7.5–20)
MTX weekly dose (mg/kg) 0.31 (0.08–0.67)
MTX weekly dose (mg/m2)b 10.2 (4.1–15.5)
Number of medications prescribed 5 (1–8)
Number of side effects recorded 3 (1–2)
Pain scalec 0.9 (0–7.1)
General evaluation scalec 0.5 (0–8.2)
CMAS scored 51.5 (42–55)
aValues represent median (range), except where indicated otherwise
bSurface area was calculated using the Mosteller method [59]
cPain scale and general evaluation scores were obtained from the patients’
Childhood Health Assessment Questionnaire
dChildhood Myositis Assessment Scale (CMAS) score was recorded for children
with JDM
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each MTXPG subgroup were also observed; that is,
short-chain MTXPGs MTXPG1–2 were highly correlated
with each other (R = 0.73, P < 0.0001), as were very long
chain polyglutamates MTXPG4–5 (R = 0.61, P < 0.0001).
The median concentration of MTXPGtotal was signifi-
cantly greater when higher MTX doses were adminis-
tered (R = 0.27, P = 0.0007). This appears to be
attributable to selective accumulation of long-chain
MTXPG3 (R = 0.28, P = 0.0005) and very long chain
MTXPG4–5 (R = 0.39–0.42, P < 0.0001) at the expense of
short-chain MTXPG1–2. This was confirmed by the per-
centage change in individual MTXPGs (relative to
MTXPGtotal) as a function of MTX dose (Fig. 1a). Inter-
estingly, concurrent administration of higher folic acid
doses was associated with increased concentrations of
shorter-chain MTXPG1–2 (R = 0.36–0.42, P = 0.002).
Similarly to previous reports [43], the dose of MTX was
higher in patients taking folic acid supplementation.
Association of methotrexate polyglutamate levels with
clinical variables
Bivariate analysis revealed significantly higher MTXPGto-
tal concentrations in patients who had MTX adminis-
tered by the SC route than among patients who received
the drug orally (median 114.1 nmol/L after SC adminis-
tration vs. 75.5 nmol/L after oral administration; P <
0.0001). When corrected for the dose administered (i.e.,
relative to 1 mg/kg or 1 mg/m2 weekly doses of MTX),
the difference in MTXPGtotal concentrations stratified by
route of administration remained significant (median
concentration 307.8 nmol/L/mg/kg vs. 236.2 nmol/L/
mg/kg dose after SC and oral administration, respect-
ively; P = 0.004; such concentrations are equivalent to
11.0 nmol/L/mg/m2 vs. 7.41 nmol/L/mg/m2, respect-
ively; P = 0.002).
Furthermore, marked differences in the distribution of
individual MTXPG concentrations according to the
route of administration were observed. Both normal and
dose-adjusted concentrations of long-chain MTXPG3
and longer-chain MTXPG4–5 were higher in patients
who received SC MTX than in patients receiving MTX.
Evaluation of the proportions of individual MTXPG sub-
types (relative to MTXPGtotal) also supported these find-
ings. The median proportions of long-chain MTXPG3 and
MTXPG4 were higher in patients treated subcutaneously
(P = 0.002 and P < 0.0001 for MTXPG3 and MTXPG4, re-
spectively), whereas the short-chain MTXPG1–2 made up
larger proportions of MTXPGs in patients treated orally
(P = 0.001 and P < 0.0001 for MTXPG1 and MTXPG2,
respectively) (Fig. 1b).
MTXPGtotal concentrations did not change signifi-
cantly with age (P > 0.05), despite the fact that older chil-
dren received significantly lower doses (per kilogram
and per square metre) of MTX (P < 0.0001). When
corrected for dose administered, however, both
MTXPGtotal and individual MTXPGs were significantly
higher in older children receiving MTX (P < 0.0001 for
MTXPGtotal; P < 0.01 for MTXPG1–2; and P < 0.001 for
MTXPG3–5) (Fig. 1c). These findings are indicative of
lower clearance rates of MTXPGs in older children than
in younger children.
Whether the patient had an underlying diagnosis of
JIA or JDM was significantly associated with varying
proportions of individual MTXPG subtypes. In particu-
lar, patients who had a diagnosis of JIA had significantly
greater proportions of short-chain MTXPG1–2 (P <
0.005), whereas long-chain MTXPG3 and very long-
chain MTXPG4 made up larger proportions of total
MTXPGs in patients diagnosed with JDM (P < 0.001 and
P = 0.009, respectively). Such differences could reflect
the fact that higher numbers of patients were treated or-
ally in the JIA subgroup (64 % treated orally in the JIA
subgroup vs. 41 % in the JDM subgroup).
Association of methotrexate polyglutamate levels with
biochemical parameters
Increased dose-normalised MTXPGtotal levels were associ-
ated with greater antiarthritic effect and improved likeli-
hood of disease control, as suggested by reduced levels of
the inflammation markers C-reactive protein (P = 0.026)
and erythrocyte sedimentation rate (ESR; P = 0.033), in pa-
tients who had higher accumulation of MTXPGtotal
concentrations.
Assessment of adherence to methotrexate therapy
Highest and lowest MTXPG levels were recorded for
each patient who had at least two measurements of their
metabolite levels during the study period (n = 40). Non-
adherence or partial adherence to MTX therapy was
identified in 17 (42.5 %) of the patients, in whom greater
than 2.0-fold variations in MTXPGtotal concentrations
were observed. Of these 17 patients, 5 (29 %) were male
and 12 (71 %) were female. They ranged in age from 7
to 17 years (median 14 years). At the time the samples
were taken, these children were supposed to be taking
between 10 and 20 mg weekly MTX doses without
change for at least 5 months. Of note, highest to lowest
MTXPG ratios, indicative of nonadherence, were signifi-
cantly greater in patients receiving smaller doses (mea-
sured as milligrams per square metre) (P < 0.031)
(Fig. 2). This suggests that patients with lower disease
activity (in whom doses were not increased as they grew)
could be associated with an increased risk of poor adher-
ence to therapy. This was particularly apparent when pa-
tients were given MTX orally in the present study
(Fig. 2). Overall, the results suggest that nearly half of
children may fail to fully comply with MTX doses as
prescribed during their long-term therapy.
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Effect of route of administration and age of child on
adherence to methotrexate
Univariate analyses showed that both the route of ad-
ministration and patient age were significantly associ-
ated with nonadherence to MTX treatment (Fig. 2). A
higher proportion of patients who received SC MTX
were found to be adherent to their medication. Only
17.6 % had greater than 2.0-fold variation in their
MTXPG levels after SC administration versus 60.8 %
of patients who received MTX orally (P = 0.005).
Fig. 1 Effect of administered dose (a), route of administration (b) and patient age (c) on the distribution of methotrexate (MTX) polyglutamates in
children receiving long-term MTX therapy
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Furthermore, adolescents and older children were
more likely than younger children to be nonadherent
to their prescribed medication; older age was signifi-
cantly correlated with greater MTXPG ratio (R = 0.35,
P = 0.026).
Sex as a variable was similarly distributed between ad-
herent and nonadherent patients. In addition, there were
no statistically significant differences in the underlying
diagnosis (JIA vs. JDM) or other obvious sociodemo-
graphic characteristics between the nonadherent group
and the remainder of the cohort (P > 0.05).
Association of nonadherence with biochemical
parameters and gastrointestinal toxicity
The frequency of MTX-related gastrointestinal (GI) side
effects (particularly the presence of nausea or vomiting)
in nonadherent patients compared with the rest of the
cohort were evaluated only in a subset of patients, be-
cause reports of nausea and vomiting were recorded
only prospectively in 19 patients of those enrolled in the
study. Of these 19 patients, 9 reported nausea, vomiting
or other GI side effects at some stage during the study.
Seven (78 %) of these patients had greater than 2.0-fold
Fig. 2 Comparison of the effects of weekly methotrexate (MTX) dose, route of administration and patient age on the highest to lowest methotrexate
polyglutamate (MTXPG) ratio recorded in children receiving long-term MTX therapy. Dashed reference line represents a ratio >2.0-fold, which is
indicative of wide fluctuations in MTXPG concentration
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variation in their MTXPG levels and therefore were con-
sidered nonadherent to therapy. The mean MTXPG ratio
in patients who reported nausea or vomiting was 3.5-fold
compared with 2.4-fold in those who did not have GI
complaints. These findings suggest that the presence
of MTX-related side effects could increase the risk of
poor adherence to MTX in children with JIA and
JDM. It is also possible that the nonadherent group
did not follow folic acid supplementation prescribed
to reduce MTX toxicity.
Finally, examining the differences in biochemical pa-
rameters between the adherent and nonadherent groups
showed a significant association between nonadherence
and elevated ESR levels (P < 0.043), suggesting an in-
creased level of inflammation and poor disease control
in nonadherent patients. This association was higher in
patients receiving MTX orally (P = 0.035).
Discussion
To our knowledge, this is the first study in which the ex-
tent of MTX adherence in paediatric patients with JIA
and JDM has been evaluated on the basis of DBS meas-
urement of MTXPGs. The approach using DBS proved
an acceptable alternative to the use of larger whole
blood or red blood cell sample quantities and had the
advantage of being minimally invasive, allowing parents
and older children to take blood samples at home. The
combination of sparse sampling and low sample volume
helped to overcome ethical and practical difficulties as-
sociated with traditional blood sampling in children and
was shown to be useful in estimating adherence.
Similarly to previous reports [44, 45], the present
study demonstrates significant interpatient variability in
total and individual MTXPG concentrations. Such vari-
ability was explained, at least in part, by MTX adminis-
tered dose, route of delivery and patient age. Higher
MTX doses were associated with greater percentage of
longer-chain MTXPG3–5 at the expense of short-chain
MTXPG1–2. Such selective enrichment of longer-chain
MTXPGs at higher doses is consistent with recent ob-
servations in children with JIA and children with acute
lymphoblastic leukaemia [45–47]. Similarly, MTXPG
distribution differed by the route of administration: Pa-
tients receiving SC MTX had higher overall levels of
MTXPGs as well as selective accumulation of longer-
chain MTXPGs. This route-dependent distribution of
MTXPGs persisted when concentrations were corrected
relative to administered dose (measured as milligrams
per kilogram or milligrams per square metre). A plaus-
ible explanation for such route-specific and dose-
dependent accumulation of long-chain MTXPGs could
be the higher concentrations produced following SC de-
livery or higher-dose administration of MTX. It has been
suggested that higher concentrations can result in a
more pronounced folate-depleted state in cells, which
activates a feedback mechanism that upregulates poly-
glutamation [45]. The stability of longer-chain polygluta-
mates would in turn allow for the preferential retention
and accumulation of long-chain MTXP3–5.
Additional factors likely to be significant contributors
to MTXPG variability include pharmacokinetic variation,
physiological and developmental differences in oral ab-
sorption, transporter expression and the individual geno-
types for MTX multiple metabolic pathways that have
been associated with both efficacy and toxicity of MTX
[48–50]. Because of the importance of folate in growth
and development in children, concurrent administration
of folic acid supplementation might also explain some of
the differences in MTXPG concentrations. This is of
particular importance in older children with higher
growth demands in puberty.
Folic acid supplementation is routinely given to reduce
potential side effects in patients receiving MTX [51, 52].
However, because MTX and folate are transported by
the same transporter within cells and compete for FPGS
for polyglutamation, it is suggested that higher intracel-
lular folate levels may trump MTX retention and affect
its polyglutamation [53, 54]. The present study shows
that folic acid use in MTX-treated children was associ-
ated with increased concentrations of short-chain
MTXPG1–2 at the expense of longer-chain MTXPG4–5.
Such an impact on MTX biotransformation leads to
either reduced MTX efficacy or higher MTX dose
requirements to achieve the same clinical effect in the
absence of folic acid.
Although inherited differences in metabolism may ex-
plain interpatient variability, they should not cause intra-
patient variability once a steady state is reached. Such
variability is hard to explain on any grounds other than
not taking the medication as prescribed. Other factors,
such as diet and alcohol intake, in teenagers could ag-
gravate this behaviour of nonadherence to prescribed
medicines. An approach to detect nonadherence in the
present study was therefore to study patients at different
times while they were prescribed the same dose of MTX
by the same route. If there were a wide variation in
MTXPGtotal concentrations at steady state, this would
most likely be a reflection of poor adherence.
According to this method, nearly half the patients had
wide fluctuations in their MTXPG concentrations indi-
cative of partial adherence or nonadherence. Interest-
ingly, doses received by nonadherent children in the
present study were significantly lower (measured as mil-
ligrams per square metre) than those prescribed to chil-
dren who were assumed to be adherent to MTX
therapy. This increased variability can be explained
partly by the children dosed with the lowest oral doses,
because such doses will have a greater proportion of
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short-chain MTXPGs that are susceptible to more signifi-
cant and rapid concentration shifts. It could also indicate
that children who received lower doses did not perceive a
high necessity for MTX therapy, owing to their low dis-
ease activity, and therefore were less likely to take their
medication consistently. Conversely, lower doses could in-
dicate an attempt to improve adherence in patients who
were more prone to MTX side effects. Further studies are
required, however, to confirm these hypotheses.
Other risk factors for nonadherence to MTX therapy in-
clude GI side effects associated with the administration of
MTX. Seven of the nine patients who reported nausea
and vomiting at some stage during the present study had
greater than 2.0-fold variation in their MTXPG levels and
therefore were considered nonadherent to therapy. Such
side effects can be diminished with SC administration of
MTX. Patients receiving the drug subcutaneously are
therefore expected to show better adherence than those
treated orally [55]. Indeed, compared with patients who
received the drug orally, a higher proportion of patients
who received SC MTX in the present study were found to
be adherent to their medication. A possible explanation
for better adherence with the SC mode of administration
could be the greater antiarthritic effect and better clinical
outcome among patients following SC MTX administra-
tion compared with those taking oral MTX, as reported in
previous studies [55–57]. However, an obvious difference
impacting adherence is the fact that SC administration is
more likely to be provided by a caregiver and thus is more
likely to be observed.
In the present study, adherence did not relate to sex
or disease type. However, a significant association be-
tween older age of children and nonadherence was
established. This is concordant with previous studies
that recognised adolescents as having lower adherence
than younger children because of their growing auton-
omy [32, 34, 58]. Older children and adolescents, there-
fore, should be monitored carefully, particularly when
they experience less severe symptoms during the stable
phases of their disease. In general, adherent patients had
better disease control throughout the study. This was
supported by elevated ESR levels, a marker of inflamma-
tion, in nonadherent patients.
A precise, sensitive and selective LC-MS/MS assay was
used for determination of MTXPGs in the present study.
Although LC-MS/MS-based methods are increasingly
used in clinical laboratories, the cost involved in sample
preparation and access to the instrument might limit its
use for routine monitoring of adherence in the clinical
setting. Another limitation of the current assay is inabil-
ity to measure the intracellular levels of relevant folate
species. The novel DBS sampling, on the other hand, has
the advantage of being both convenient for home sam-
pling and a direct objective measure of adherence. An
additional obvious benefit is the lower blood volume re-
quirement applicable for monitoring MTXPGs in
children.
Conclusions
The present study is unique in being the first detailed ana-
lysis of MTXPG levels based on DBS measurements in
JIA and JDM. Our data highlight the significance of non-
adherence to MTX therapy in patients with JIA and JDM
and demonstrate the feasibility of measuring MTXPGs in
DBS samples as a potential tool to monitor adherence.
We also explored the pattern of variability in MTXPG
concentrations and its association with clinical variables
and additional biochemical parameters pertaining to dis-
ease activity and MTX side effects. The findings warrant
further investigation into the clinical utility of MTXPG
levels to guide therapy and optimise adherence to MTX
treatment in children. Furthermore, the study highlights
the importance of understanding the potential barriers to
MTX adherence in order to help manage the disease and
improve patients’ quality of life.
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